Topical acne treatments in Europe and the issue of antimicrobial resistance

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 8, 2015, Pages 1485-1492

  Leccia, M T ^a   Auffret, N ^b   Poli, F ^b   Claudel, J P ^c   Corvec, S ^d   Dreno, B ^e  

^a HÔPITAL MICHALLON   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c Private Practice   (France)

^d INSTITUT DE BIOLOGIE   (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; ANTI ACNE AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZELAIC ACID; BENZOYL PEROXIDE; CLINDAMYCIN; ERYTHROMYCIN; RETINOIC ACID; RETINOID; ZINC;

ACNE; ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; EUROPE; HUMAN; IMMUNITY; MONOTHERAPY; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; REVIEW; TOPICAL TREATMENT; ACNE VULGARIS; DRUG EFFECTS; TOPICAL DRUG ADMINISTRATION;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; EUROPE; HUMANS; PROPIONIBACTERIUM ACNES;

EID: 84948714960     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12989     Document Type: Review

References (120)

1. Bellew S, Thiboutot D, Del Rosso JQ,. Pathogenesis of acne vulgaris: what's new, what's interesting and what may be clinically relevant. J Drugs Dermatol 2011; 10: 582-585.
2. Bhambri S, Del Rosso JQ, Bhambri A,. Pathogenesis of acne vulgaris: recent advances. J Drugs Dermatol 2009; 8: 615-618.
3. Grice EA, Segre JA,. The skin microbiome. Nat Rev Microbiol 2011; 9: 244-253.
4. Beylot C, Auffret N, Poli F, et al,. Propionibacterium acnes: an update on its role in the pathogenesis of acne. J Eur Acad Dermatol Venereol 2014; 28: 271-278.
5. Strauss JS, Krowchuk DP, Leyden JJ, et al,. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007; 56: 651-663.
6. Nast A, Dreno B, Bettoli V, et al,. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol 2012; 26 (Suppl 1): 1-29.
7. Thiboutot D, Gollnick H, Bettoli V, et al,. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009; 60 (5 Suppl): S1-S50.
8. Gollnick H, Cunliffe W, Berson D, et al,. Management of acne: a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol 2003; 49 (1 Suppl): S1-S37.
9. Thiboutot D, Dreno B, Gollnick H, et al,. A call to limit antibiotic use in acne. J Drugs Dermatol 2013; 12: 1331-1332.
10. Dreno B, Thiboutot D, Gollnick H, et al,. Antibiotic stewardship in dermatology: limiting antibiotic use in acne. Eur J Dermatol 2014; 24: 330-334.
11. Feneran AN, Kaufman WS, Dabade TS, Feldman SR,. Retinoid plus antimicrobial combination treatments for acne. Clin Cosmet Investig Dermatol 2011; 4: 79-92.
12. Tenson T, Lovmar M, Ehrenberg M,. The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Biol 2003; 330: 1005-1014.
13. Lee WL, Shalita AR, Suntharalingam K, Fikrig SM,. Neutrophil chemotaxis by Propionibacterium acnes lipase and its inhibition. Infect Immun 1982; 35: 71-78.
14. Hooper DC,. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis 2000; 31 (Suppl 2): S24-S28.
15. Alba V, Urban E, Angeles DM, et al,. In vitro activity of nadifloxacin against several Gram-positive bacteria and analysis of the possible evolution of resistance after 2 years of use in Germany. Int J Antimicrob Agents 2009; 33: 272-275.
16. Wozel G, Blasum C,. Dapsone in dermatology and beyond. Arch Dermatol Res 2014; 306: 103-124.
17. Jones EL, Crumley AF,. Topical erythromycin vs blank vehicle in a multiclinic acne study. Arch Dermatol 1981; 117: 551-553.
18. Dobson RL, Belknap BS,. Topical erythromycin solution in acne. Results of a multiclinic trial. J Am Acad Dermatol 1980; 3: 478-482.
19. Lesher JL Jr, Chalker DK, Smith JG Jr, et al,. An evaluation of a 2% erythromycin ointment in the topical therapy of acne vulgaris. J Am Acad Dermatol 1985; 12: 526-531.
20. Plewig G, Holland KT, Nenoff P,. Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris: a double-blind, phase III comparison study versus erythromycin 2% cream. Eur J Dermatol 2006; 16: 48-55.
21. Choudhury S, Chatterjee S, Sarkar DK, Dutta RN,. Efficacy and safety of topical nadifloxacin and benzoyl peroxide versus clindamycin and benzoyl peroxide in acne vulgaris: a randomized controlled trial. Indian J Pharmacol 2011; 43: 628-631.
22. Tunca M, Akar A, Ozmen I, Erbil H,. Topical nadifloxacin 1% cream vs. topical erythromycin 4% gel in the treatment of mild to moderate acne. Int J Dermatol 2010; 49: 1440-1444.
23. Jung JY, Kwon HH, Yeom KB, Yoon MY, Suh DH,. Clinical and histological evaluation of 1% nadifloxacin cream in the treatment of acne vulgaris in Korean patients. Int J Dermatol 2011; 50: 350-357.
24. Zouboulis CC, Derumeaux L, Decroix J, Maciejewska-Udziela B, Cambazard F, Stuhlert A,. A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (Dalacin T) applied twice daily in the topical treatment of acne vulgaris. Br J Dermatol 2000; 143: 498-505.
25. Schmidt N, Gans EH,. Clindamycin 1.2% Tretinoin 0.025% Gel versus Clindamycin Gel treatment in acne patients: a focus on Fitzpatrick skin types. J Clin Aesthet Dermatol 2011; 4: 31-40.
26. Draelos ZD, Carter E, Maloney JM, et al,. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol 2007; 56: 439.
27. Lynde CW, Andriessen A,. Cohort study on the treatment with dapsone 5% gel of mild to moderate inflammatory acne of the face in women. Skinmed 2014; 12: 15-21.
28. Pickert A, Raimer S,. An evaluation of dapsone gel 5% in the treatment of acne vulgaris. Expert Opin Pharmacother 2009; 10: 1515-1521.
29. Lucky AW, Maloney JM, Roberts J, et al,. Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment. J Drugs Dermatol 2007; 6: 981-987.
30. Leyden JJ,. Antibiotic resistant acne. Cutis 1976; 17: 593-596.
31. Cooper AJ,. Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Med J Aust 1998; 169: 259-261.
32. Coates P, Vyakrnam S, Eady EA, Jones CE, Cove JH, Cunliffe WJ,. Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study. Br J Dermatol 2002; 146: 840-848.
33. Marr JK, Lim AT, Yamamoto LG,. Erythromycin-induced resistance to clindamycin in Staphylococcus aureus. Hawaii Med J 2005; 64: 6-8.
34. Gupta V, Datta P, Rani H, Chander J,. Inducible clindamycin resistance in Staphylococcus aureus: a study from North India. J Postgrad Med 2009; 55: 176-179.
35. Ross JI, Snelling AM, Carnegie E, et al,. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol 2003; 148: 467-478.
36. Dumont-Wallon G, Moyse D, Blouin E, Dréno B,. Bacterial resistance in French acne patients. Int J Dermatol 2010; 49: 283-288.
37. CDC. ANTIBIOTIC RESISTANCE THREATS in the United States, 2013 Centers for Disease Control and Prevention2013. Available from: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. (last accessed: 16 October 2013).
38. Organization WH. The evolving threat of antimicrobial resistance-Options for action 2012. Available from: http://www.who.int/patientsafety/implementation/amr/publication/en/index.html (last accessed 16 October 2013).
39. Pal N, Sharma B, Sharma R, Vyas L,. Detection of inducible clindamycin resistance among Staphylococcal isolates from different clinical specimens in western India. J Postgrad Med 2010; 56: 182-185.
40. Delyle LG, Vittecoq O, Bourdel A, Duparc F, Michot C, Le Loet X,. Chronic destructive oligoarthritis associated with Propionibacterium acnes in a female patient with acne vulgaris: septic-reactive arthritis? Arthritis Rheum 2000; 43: 2843-2847.
41. Kouyoumdjian GA, Larkin TP, Blackburn PJ, Mandava N,. Optic disk edema as a presentation of Propionibacterium acnes endophthalmitis. Am J Ophthalmol 2001; 132: 259-261.
42. Walti LN, Conen A, Coward J, Jost GF, Trampuz A,. Characteristics of infections associated with external ventricular drains of cerebrospinal fluid. J Infect 2013; 66: 424-431.
43. Charles P, Hot A, Ou P, et al,. Propionibacterium acnes endocarditis in an adolescent boy suffering from a congenital cardiopathy. Pediatr Infect Dis J 2007; 26: 856-858.
44. Aubin GG, Portillo ME, Trampuz A, Corvec S,. Propionibacterium acnes, an emerging pathogen: from acne to implant-infections, from phylotype to resistance. Med Mal Infect 2014; 44: 241-250.
45. Merker PC,. Benzoyl peroxide: a history of early research and researchers. Int J Dermatol 2002; 41: 185-188.
46. Dutil M,. Benzoyl peroxide: enhancing antibiotic efficacy in acne management. Skin Therapy Lett 2010; 15: 5-7.
47. Sagransky M, Yentzer BA, Feldman SR,. Benzoyl peroxide: a review of its current use in the treatment of acne vulgaris. Expert Opin Pharmacother 2009; 10: 2555-2562.
48. Mills OH, Kligman AM, Pochi P, Comite H,. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol 1986; 25: 664-667.
49. Hegemann L, Toso SM, Kitay K, Webster GF,. Anti-inflammatory actions of benzoyl peroxide: effects on the generation of reactive oxygen species by leucocytes and the activity of protein kinase C and calmodulin. Br J Dermatol 1994; 130: 569-575.
50. Hughes BR, Norris JF, Cunliffe WJ,. A double-blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne. Clin Exp Dermatol 1992; 17: 165-168.
51. Leyden JJ, McGinley KJ, Cavalieri S, Webster GF, Mills OH, Kligman AM,. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983; 8: 41-45.
52. Savage LJ, Layton AM,. Treating acne vulgaris: systemic, local and combination therapy. Expert Rev Clin Pharmacol 2010; 3: 563-580.
53. Bojar RA, Cunliffe WJ, Holland KT,. The short-term treatment of acne vulgaris with benzoyl peroxide: effects on the surface and follicular cutaneous microflora. Br J Dermatol 1995; 132: 204-208.
54. James WD,. Clinical practice. Acne. N Engl J Med 2005; 352: 1463-1472.
55. Leyden JJ, Wortzman M, Baldwin EK,. Antibiotic-resistant Propionibacterium acnes suppressed by a benzoyl peroxide cleanser 6%. Cutis 2008; 82: 417-421.
56. Lookingbill DP, Chalker DK, Lindholm JS, et al,. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol 1997; 37: 590-595.
57. Chalker DK, Shalita A, Smith JG Jr, Swann RW,. A double-blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. J Am Acad Dermatol 1983; 9: 933-936.
58. Babaeinejad SH, Fouladi RF,. The efficacy, safety and tolerability of adapalene versus benzoyl peroxide in the treatment of mild acne vulgaris; a randomized trial. J Drugs Dermatol 2013; 12: 1033-1038.
59. Shwereb C, Lowenstein EJ,. Delayed type hypersensitivity to benzoyl peroxide. J Drugs Dermatol 2004; 3: 197-199.
60. Minciullo PL, Patafi M, Giannetto L, et al,. Allergic contact angioedema to benzoyl peroxide. J Clin Pharm Ther 2006; 31: 385-387.
61. Leyden J,. Adapalene in clinical practice. Cutis 2001; 68 (4 Suppl): 7-9.
62. Bershad S, Poulin YP, Berson DS, et al,. Topical retinoids in the treatment of acne vulgaris. Cutis 1999; 64 (Suppl. 2): 8-20; quiz 1-3.
63. Liu PT, Krutzik SR, Kim J, Modlin RL,. Cutting edge: all-trans retinoic acid down-regulates TLR2 expression and function. J Immunol 2005; 174: 2467-2470.
64. Jalian HR, Liu PT, Kanchanapoomi M, Phan JN, Legaspi AJ, Kim J,. All-trans retinoic acid shifts Propionibacterium acnes-induced matrix degradation expression profile toward matrix preservation in human monocytes. J Invest Dermatol 2008; 128: 2777-2782.
65. Michel S, Jomard A, Demarchez M,. Pharmacology of adapalene. Br J Dermatol 1998; 139 (Suppl 52): 3-7.
66. Tenaud I, Khammari A, Dreno B,. In vitro modulation of TLR-2, CD1d and ILL-10 by adapalene on normal human skin and acne inflammatory lesions. Exp Dermatol 2007; 16: 500-506.
67. Wolf JE Jr,. Potential anti-inflammatory effects of topical retinoids and retinoid analogues. Adv Ther 2002; 19: 109-118.
68. Webster GF,. Topical tretinoin in acne therapy. J Am Acad Dermatol 1998; 39: S38-S44.
69. Krautheim A, Gollnick HP,. Acne: topical treatment. Clin Dermatol 2004; 22: 398-407.
70. Schorr ES, Sidou F, Kerrouche N,. Adjunctive use of a facial moisturizer SPF 30 containing ceramide precursor improves tolerability of topical tretinoin 0.05%: a randomized, investigator-blinded, split-face study. J Drugs Dermatol 2012; 11: 1104-1107.
71. Gollnick HP, Krautheim A,. Topical treatment in acne: current status and future aspects. Dermatology 2003; 206: 29-36.
72. Thielitz A, Gollnick H,. Topical retinoids in acne vulgaris: update on efficacy and safety. Am J Clin Dermatol 2008; 9: 369-381.
73. Cunliffe WJ, Poncet M, Loesche C, Verschoore M,. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol 1998; 139 (Suppl 52): 48-56.
74. Phillips TJ,. An update on the safety and efficacy of topical retinoids. Cutis 2005; 75 (Suppl. 2): 14-22, 4; discussion -3.
75. Dunlap FE, Mills OH, Tuley MR, Baker MD, Plott RT,. Adapalene 0.1% gel for the treatment of acne vulgaris: its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference. Br J Dermatol 1998; 139 (Suppl. 52): 17-22.
76. Dosik JS, Homer K, Arsonnaud S,. Cumulative irritation potential of adapalene 0.1% cream and gel compared with tretinoin microsphere 0.04% and 0.1%. Cutis 2005; 75: 238-243.
77. Brand B, Gilbert R, Baker MD, et al,. Cumulative irritancy comparison of adapalene gel 0.1% versus other retinoid products when applied in combination with topical antimicrobial agents. J Am Acad Dermatol 2003; 49 (Suppl. 3): S227-S232.
78. Rizova E, Pagnoni PA, Stoudemayer T, Poncet M, Kligman AM,. Polarized light photography and videomicroscopy greatly enhance the capability of estimating the therapeuic response to a topical retinoid (adapalene) in acne vulgaris. Cutis 2001; 68 (4 Suppl): 25-33.
79. Liu PT, Phan J, Tang D, et al,. CD209(+) macrophages mediate host defense against Propionibacterium acnes. J Immunol 2008; 180: 4919-4923.
80. Usatine RP, Quan MA,. Pearls in the management of acne: an advanced approach. Prim Care 2000; 27: 289-308.
81. Bojar RA, Cutcliffe AG, Graupe K, Cunliffe WJ, Holland KT,. Follicular concentrations of azelaic acid after a single topical application. Br J Dermatol 1993; 129: 399-402.
82. Leeming JP, Holland KT, Bojar RA,. The in vitro antimicrobial effect of azelaic acid. Br J Dermatol 1986; 115: 551-556.
83. Topert M, Rach P, Siegmund F,. Pharmacology and toxicology of azelaic acid. Acta Derm Venereol Suppl (Stockh) 1989; 143: 14-19.
84. Schallreuter KU, Wood JM,. Azelaic acid as a competitive inhibitor of thioredoxin reductase in human melanoma cells. Cancer Lett 1987; 36: 297-305.
85. Stamatiadis D, Bulteau-Portois MC, Mowszowicz I,. Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol 1988; 119: 627-632.
86. Passi S, Picardo M, Mingrone G, Breathnach AS, Nazzaro-Porro M,. Azelaic acid-biochemistry and metabolism. Acta Derm Venereol Suppl (Stockh) 1989; 143: 8-13.
87. Galhaup I,. Azelaic acid: mode of action at cellular and subcellular levels. Acta Derm Venereol Suppl (Stockh) 1989; 143: 75-82.
88. Gollnick HP, Graupe K, Zaumseil RP,. Azelaic acid 15% gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. J Dtsch Dermatol Ges 2004; 2: 841-847.
89. Thiboutot D,. Versatility of azelaic acid 15% gel in treatment of inflammatory acne vulgaris. J Drugs Dermatol 2008; 7: 13-16.
90. Bladon PT, Burke BM, Cunliffe WJ, Forster RA, Holland KT, King K,. Topical azelaic acid and the treatment of acne: a clinical and laboratory comparison with oral tetracycline. Br J Dermatol 1986; 114: 493-499.
91. Swanson JK,. Antibiotic resistance of Propionibacterium acnes in acne vulgaris. Dermatol Nurs 2003; 15: 359-362.
92. Gollnick H, Schramm M,. Topical drug treatment in acne. Dermatology 1998; 196: 119-125.
93. Arshdeep, De D,. What's new in the management of acne? Indian J Dermatol Venereol Leprol 2013; 79: 279-287.
94. Warner GT, Plosker GL,. Clindamycin/benzoyl peroxide gel: a review of its use in the management of acne. Am J Clin Dermatol 2002; 3: 349-360.
95. McKeage K, Keating GM,. Clindamycin/benzoyl peroxide gel (BenzaClin): a review of its use in the management of acne. Am J Clin Dermatol 2008; 9: 193-204.
96. Thiboutot D, Zaenglein A, Weiss J, Webster G, Calvarese B, Chen D,. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol 2008; 59: 792-800.
97. Langner A, Sheehan-Dare R, Layton A,. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris. J Eur Acad Dermatol Venereol 2007; 21: 311-319.
98. Del Rosso JQ,. Study results of benzoyl peroxide 5%/clindamycin 1% topical gel, adapalene 0.1% gel, and use in combination for acne vulgaris. J Drugs Dermatol 2007; 6: 616-622.
99. Leyden JJ, Hickman JG, Jarratt MT, Stewart DM, Levy SF,. The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J Cutan Med Surg 2001; 5: 37-42.
100. Harkaway KS, McGinley KJ, Foglia AN, et al,. Antibiotic resistance patterns in coagulase-negative staphylococci after treatment with topical erythromycin, benzoyl peroxide, and combination therapy. Br J Dermatol 1992; 126: 586-590.
101. Thong BY, Mirakian R, Castells M, et al,. A world allergy organization international survey on diagnostic procedures and therapies in drug allergy/hypersensitivity. World Allergy Organ J 2011; 4: 257-270.
102. Eady EA, Farmery MR, Ross JI, Cove JH, Cunliffe WJ,. Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic-sensitive and -resistant skin bacteria from acne patients. Br J Dermatol 1994; 131: 331-336.
103. Dreno B, Foulc P, Reynaud A, Moyse D, Habert H, Richet H,. Effect of zinc gluconate on Propionibacterium acnes resistance to erythromycin in patients with inflammatory acne: in vitro and in vivo study. Eur J Dermatol 2005; 15: 152-155.
104. Dreno B, Trossaert M, Boiteau HL, Litoux P,. Zinc salts effects on granulocyte zinc concentration and chemotaxis in acne patients. Acta Derm Venereol 1992; 72: 250-252.
105. Jarrousse V, Castex-Rizzi N, Khammari A, Charveron M, Dreno B,. Zinc salts inhibit in vitro Toll-like receptor 2 surface expression by keratinocytes. Eur J Dermatol 2007; 17: 492-496.
106. Santos MC, Souza AP, Gerlach RF, Tabchoury CM, Line SR,. Inhibition of human gelatinases (matrix metalloproteinase-2 and matrix metalloproteinase-9) activity by zinc oxide: a possible mechanism to enhance wound healing. Br J Dermatol 2001; 145: 854-855.
107. Brocard A, Dreno B,. Innate immunity: a crucial target for zinc in the treatment of inflammatory dermatosis. J Eur Acad Dermatol Venereol 2011; 25: 1146-1152.
108. Sugimoto Y, Lopez-Solache I, Labrie F, Luu-The V,. Cations inhibit specifically type I 5 alpha-reductase found in human skin. J Invest Dermatol 1995; 104: 775-778.
109. Bojar RA, Eady EA, Jones CE, Cunliffe WJ, Holland KT,. Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. Br J Dermatol 1994; 130: 329-336.
110. Cunliffe WJ, Fernandez C, Bojar R, Kanis R, West F, Group ZCS. An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. J Dermatolog Treat 2005; 16: 213-218.
111. Schachner L, Pestana A, Kittles C,. A clinical trial comparing the safety and efficacy of a topical erythromycin-zinc formulation with a topical clindamycin formulation. J Am Acad Dermatol 1990; 22: 489-495.
112. Korting HC, Braun-Falco O,. Efficacy and tolerability of combined topical treatment of acne vulgaris with tretinoin and erythromycin in general practice. Drugs Exp Clin Res 1989; 15: 447-451.
113. Kreusch J, Bextermoller R,. Efficacy and tolerability of a topical erythromycin/tretinoin combination preparation in acne treatment: post-marketing surveillance study involving over 6500 patients. Curr Med Res Opin 2000; 16: 1-7.
114. Thiboutot DM, Weiss J, Bucko A, et al,. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 2007; 57: 791-799.
115. Gold LS, Cruz A, Eichenfield L, et al,. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle-controlled, double-blind study of adapalene 0.1%-benzoyl peroxide 2.5% fixed-dose combination gel with doxycycline hyclate 100 mg. Cutis 2010; 85: 94-104.
116. Gold LS, Tan J, Cruz-Santana A, et al,. A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. Cutis 2009; 84: 110-116.
117. Zhou R, Jiang X,. Effects of adapalene-benzoyl peroxide combination gel in treatment or maintenance therapy of moderate or severe acne vulgaris: a meta-analysis. Ann Dermatol 2014; 26: 43-52.
118. Bettoli V, Borghi A, Zauli S, et al,. Maintenance Therapy for Acne Vulgaris: efficacy of a 12-month treatment with adapalene-benzoyl peroxide after oral isotretinoin and a review of the literature. Dermatology 2013; 227: 97-102.
119. Poulin Y, Sanchez NP, Bucko A, et al,. A 6-month maintenance therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial. Br J Dermatol 2011; 164: 1376-1382.
120. Gold MH, Rao J, Goldman MP, et al,. A multicenter clinical evaluation of the treatment of mild to moderate inflammatory acne vulgaris of the face with visible blue light in comparison to topical 1% clindamycin antibiotic solution. J Drugs Dermatol 2005; 4: 64-70.